Upload File

The top documents tagged [discontinued treatment]

Effect of Rosuvastatin Versus Placebo on Cardiovascular Outcomes in Patients with End-Stage Renal Disease on Hemodialysis – Results of the AURORA Study
Effect of Rosuvastatin Versus Placebo on Cardiovascular Outcomes in Patients with End-Stage Renal Disease on Hemodialysis – Results of the AURORA Study
220 views
Experience with Antibody-Mediated Rejection Millie Samaniego, M.D. Associate Professor of Medicine University of Wisconsin and Robert A. Montgomery, M.D.,
Experience with Antibody-Mediated Rejection Millie Samaniego, M.D. Associate Professor of Medicine University of Wisconsin and Robert A. Montgomery, M.D.,
215 views
how_long_do_treatment_effects_last._persistence_and_durability_of_a_descriptive_norms_interventions_effect_on_energy_conservation.pdf
how_long_do_treatment_effects_last._persistence_and_durability_of_a_descriptive_norms_interventions_effect_on_energy_conservation.pdf
212 views
TREATMENT NON-COMPLIANCE IN PSYCHIATRY. NON-COMPLIANCE: PREVALENCE REASONS CLINICAL CONSEQUENCES - Dr. Ashish Srivastava, M.D
TREATMENT NON-COMPLIANCE IN PSYCHIATRY. NON-COMPLIANCE: PREVALENCE REASONS CLINICAL CONSEQUENCES - Dr. Ashish Srivastava, M.D
215 views
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD Swedish Cancer Institute Seattle, WA Global Resource for
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD Swedish Cancer Institute Seattle, WA Global Resource for
216 views
PERINATAL MOOD DISORDERS: Update on Psychotropic Prescribing
PERINATAL MOOD DISORDERS: Update on Psychotropic Prescribing
216 views
Genitourinary Oncology ASCO 2009 Toni K. Choueiri, MD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts U.S.A
Genitourinary Oncology ASCO 2009 Toni K. Choueiri, MD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts U.S.A
216 views
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD
34 views
2 Lucio Crinò Medical Oncology Department University Hospital Perugia, Italy The optimal therapeutic algorithm for EML4-ALK + ve pts
2 Lucio Crinò Medical Oncology Department University Hospital Perugia, Italy The optimal therapeutic algorithm for EML4-ALK + ve pts
217 views
Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of Overall Survival for
Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of Overall Survival for
225 views
Background
Background
32 views
Kenneth W. Mahaffey, MD, on behalf of the TRACER Investigators and Committees
Kenneth W. Mahaffey, MD, on behalf of the TRACER Investigators and Committees
53 views